Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination

Andorko, James I.; Tsai, Shannon; Gammon, Joshua M.; Carey, Sean T; Zeng, Xianyi; Gosselin, Emily A.; Edwards, Camilla; Shah, Siddharth; Hess, Krystina L.; Jewell, Christopher M.

doi:10.1039/d2bm00403h

Cited by 5 publications

(3 citation statements)

References 57 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delivery of both adjuvant and antigen in the same LN was shown to provide stronger protection against tumors than splitting the signals between distinct LNs. 61 The requirement for both signals to be localized to the same geographic location suggests that the two signals work together within the LN to promote expansion of tumor-killing T cells (Figure 5F). In additional studies, we used the modularity of the MP platform to incorporate additional drugs to further condition phenotype such as low-dose mTOR inhibitors to drive central memory T cells.…”

Section: Acsmentioning

confidence: 99%

“…In a model of cancer, signals split between contralateral LNs remained separate as shown via in vivo imaging (Figure D,E). Delivery of both adjuvant and antigen in the same LN was shown to provide stronger protection against tumors than splitting the signals between distinct LNs . The requirement for both signals to be localized to the same geographic location suggests that the two signals work together within the LN to promote expansion of tumor-killing T cells (Figure F).…”

Section: Direct Targeting Of Immunological Niches/metabolismmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy

Edwards

Carey

Jewell

2023

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

Immunotherapies are an evolving treatment paradigm for addressing cancer, autoimmunity, and infection. While exciting, most of the existing therapies are limited by their specificity�unable to differentiate between healthy and diseased cells at an antigen-specific level. Biomaterials are a powerful tool that enable the development of next-generation immunotherapies due to their tunable synthesis properties. Our lab harnesses biomaterials as tools to study antigen-specific immunity and as technologies to enable new therapeutic vaccines and immunotherapies to combat cancer, autoimmunity, and infections. Our efforts have spanned the study of intrinsic immune profiles of biomaterials, development of novel nanotechnologies assembled entirely from immune cues, manipulation of innate immune signaling, and advanced technologies to direct and control specialized immune niches such as skin and lymph nodes.

show abstract

Section: Acsmentioning

confidence: 99%

Section: Direct Targeting Of Immunological Niches/metabolismmentioning

confidence: 99%

Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy

Edwards

Carey

Jewell

2023

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 108 ] Further, alterations to the lymph node microenvironment were highly localized to the injected lymph node. [ 109 ] When loaded with myelin self‐antigen and rapamycin, iLN injected particles were shown to induce significant expansion of T REG compared to soluble controls. Additionally, iLN MPs were able to reverse paralysis in mouse EAE in an antigen specific manner with a one‐time treatment at peak disease [ 110 ] (Figure 6B).…”

Section: Biomaterials Localize Cargo In Tissues That Support Toleroge...mentioning

confidence: 99%

Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps

2023

Self Cite

View full text Add to dashboard Cite

Autoimmunity and allergies affect a large number of people across the globe. Current approaches to these diseases target cell types and pathways that drive disease, but these approaches are not cures and cannot differentiate between healthy cells and disease‐causing cells. New immunotherapies that induce potent and selective antigen‐specific tolerance is a transformative goal of emerging treatments for autoimmunity and serious allergies. These approaches offer the potential of halting—or even reversing—disease, without immunosuppressive side effects. However, translating successful induction of tolerance to patients is unsuccessful. Biomaterials offer strategies to direct and maximize immunological mechanisms of tolerance through unique capabilities such as codelivery of small molecules or signaling molecules, controlling signal density in key immune tissues, and targeting. While a growing body of work in this area demonstrates success in preclinical animal models, these therapies are only recently being evaluated in human trials. This review will highlight the most recent advances in the use of materials to achieve antigen‐specific tolerance and provide commentary on the current state of the clinical development of these technologies.

show abstract

Nano/genetically engineered cells for immunotherapy

Shen,

Zhou,

Yin

2024

BMEMat

View full text Add to dashboard Cite

Immunotherapy has recently emerged as a promising therapeutic modality for the treatment of various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. Despite its potential, immunotherapy faces challenges related to delivery efficiency and off‐target toxicity of immunotherapeutic drugs. Nano drug delivery systems offer improvements in drug biodistribution and release kinetics but still suffer from shortcomings such as high immunogenicity, poor penetration across biological barriers, and insufficient tissue permeability. Targeted delivery of drugs using living cells has become an emerging strategy that can take advantage of the inherent characteristics of cells to deal with the delivery defects of nano delivery systems. Furthermore, cells themselves can be genetically engineered into cellular drugs for enhanced immunotherapy. This review provides an in‐depth exploration of cell‐derived drug carriers, detailing their biological properties, functions, and commonly used drug loading strategies. In addition, the role of genetically modified cells in immunotherapy and their synergistic therapeutic effects with drug delivery are also introduced. By summarizing the main advancements and limitations in the field, this review offers insights into the potential of cell‐based drug delivery systems to address the existing challenges in immunotherapy. The introduction to recent developments and evaluation of ongoing research will pave the way for the optimization and widespread adoption of nano/genetically engineered cells for immunotherapy.

show abstract

Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination

Abstract: Recently approved cancer immunotherapies – including CAR-T cells and cancer vaccination, show great promise. However, these technologies are hindered by the complexity and cost of isolating and engineering patient cells...

Cited by 5 publications

References 57 publications

Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy

Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy

Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps

Nano/genetically engineered cells for immunotherapy

Contact Info

Product

Resources

About